Biohaven Ltd. (NYSE: BHVN) announced the enrollment of the first patient in a pivotal Phase 3 trial of BHV-1300, a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE